Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Table 1

The characteristics of included studies.

Author	Year	Cases; T/C	Age (years) range, mean	Sex: male/female	Interventions		Duration (wk)/; follow-up (wk)	Adverse events	Outcome measures
					Trials group	Control group
Zhao; et al. [12]	2010	40/43	T: 16–62, 35; C: 16–62, 37	T: 25/15; C: 27/16	KS + LAM	LAM	48/NR	T: 4 cases and C: 5 cases with light digestive tract side-effect	HBeAg loss; HBeAg sero; HBV-DNA; ALT; AST; TER
Chen and Yang [13]	2010	70/70	T: 19–60, 34; C: 20–61, 33	T: 40/30; C: 42/28	KS + LAM	LAM	48/NR	NR	HBeAg loss; HBeAg sero; HBV-DNA; ALT norm; AST norm; ALT; AST
Shi; et al. [14]	2010	48/44	T: 16–60, 32; C: 17–59, 32	T: 28/20; C: 25/19	KS + LAM	LAM	48/NR	Trials group had light digestive tract side-effect at first and then symptoms disappeared	HBeAg loss; HBeAg sero; HBV-DNA; ALT norm
Ma [15]	2011	26/20	T: 18–60; C: 18–60	30/16	KS + LAM	LAM	48/NR	0	HBeAg loss; HBV-DNA; ALT norm; AST norm; ALT; AST; TBIL
Zhang [16]	2012	50/50	T: 18–62, 36; C: 19–63, 36	T: 28/22; C: 29/21	KS + LAM	LAM	48/NR	0	HBeAg loss; HBV-DNA; ALT norm; AST norm
Zhou [17]	2013	62/68	T: 20–69, 42; C: 18–69, 40	T: 42/20; C: 46/22	KS + LAM	LAM	48/NR	NR	HBeAg loss; HBV-DNA; ALT; AST
Shao and Zhang [18]	2010	48/48	T: 19–64, 34; C: 19–64, 34	63/29	KS + ETV	ETV	48/NR	NR	HBeAg loss; HBeAg sero; HBV-DNA; ALT norm
Yi; et al. [19]	2012	92/95	T: 18–65; C: 18–65	NR	KS + ETV	ETV	48/NR	T: 1 with light digestive tract side-effect	HBeAg loss; HBeAg sero; ALT norm
J. G. Yu and; B. H. Yu [20]	2012	40/43	T: 18–50, 35; C: 18–50, 35	65/18	KS + ETV	ETV	48/NR	0	HBeAg loss; HBsAg loss; HBV-DNA; ALT norm
Ren; et al. [21]	2014	52/48	T: 41–56, 47; C: 41–56, 47	53/47	KS + ETV	ETV	48/NR	T: 1 case and C: 2 cases with dizziness	HBeAg loss; HBV-DNA; ALT norm
Liu; et al. [22]	2007	34/30	T: 16–65; C: 16–65	32/24	KS + ADV	ADV	48/24	0	HBeAg loss; HBsAg loss; HBV-DNA; TER
Yang; et al. [23]	2011	40/40	T: 22–48, 37; C: 22–48, 37	48/32	KS + ADV	ADV	48/NR	Light digestive tract side-effect at first	HBeAg sero; HBV-DNA
Hu and Sun [24]	2012	54/52	T: 16–65, 29; C: 16–65	T: 38/16; C: 34/18	KS + ADV	ADV	48/NR	T: 4 cases and C: 2 cases with light digestive tract side-effect	HBeAg loss; HBeAg sero; HBV-DNA
Jiang [25]	2013	45/45	T: 19–49, 31; C: 18–52, 32	T: 30/15; C: 28/17	KS + ADV	ADV	48/NR	NR	HBeAg loss; HBV-DNA
Xu and; Liang [26]	2013	40/40	NR	NR	KS + ADV	ADV	48/NR	T: 6 cases and C: 4 cases with dizziness and fatigue	HBeAg loss; HBV-DNA; ALT norm
Chen; et al. [27]	2009	35/27	T: 29; C: 30	T: 24/11; C: 19/8	KS + TLV	TLV	48/NR	0	HBeAg loss; HBeAg sero; HBV-DNA; ALT; AST; TBIL
Yu [28]	2012	30/30	T: 18–50, 35; C: 18–50, 35	T: 23/7; C: 22/8	KS + TLV	TLV	48/NR	0	HBeAg loss; HBV-DNA; ALT norm; ALT; TER
Yang and Zeng [29]	2013	43/42	T: 18–60, 30; C: 18–62, 31	T: 25/18; C: 25/17	KS + TLV	TLV	48/NR	0	HBeAg sero; HBV-DNA

The different authors with the same name in English.
KS: Kushenin, 0.6 g/d; LAM: lamivudine, 0.1 g/d; ETV: entecavir, 0.5 mg/d; ADV: adefovir dipivoxil, 10 mg/d; TLV: telbivudine, 600 mg/d.
HBeAg loss: hepatitis B e antigen loss; HBsAg loss: hepatitis B s antigen loss; HBeAg sero: hepatitis B e antigen seroconversion; HBV-DNA: undetectable HBV-DNA levels; ALT norm: normalization of serum alanine aminotransferase levels; AST norm: normalization of serum aspartate transaminase levels; ALT: serum ALT level; AST: serum AST level; TBIL: serum TBIL level; TER: total efficacy rate (serum level of ALT decreases at least 25% and serum level of AST decreases at least 50%).